The average U.S. public firm spent $1.294 million less on R&D after the SEC's 2005 mandate to disclose risk factors, according to a study of 5,202 companies covering roughly 40,000 firm-years from 1994 to 2010. Shiu-Yik Au of the University of Manitoba and Hongping Tan of McGill University report that the same regulation cost firms 0.371 patents each, cut citations per patent by 0.654, and reduced average patent value by $1.929 million.

The paper, forthcoming in the Journal of Accounting and Public Policy, exploits the SEC's 2005 requirement under Item 503(c) of Regulation S-K that listed firms disclose risks in the Item 1A Risk Factors section. The authors limited their sample to firms that either reported more than $0 in R&D expenses or held at least one patent over the sample period, ensuring the dataset captured actual innovators rather than firms with no innovation activity to constrain.

The findings matter for R&D managers because they show the disclosure regime did not just trim budgets — it changed what firms chose to build. After the mandate, corporate patenting shifted from exploratory patents, which pursue novel technologies, toward exploitative patents that leverage existing technology. Capital expenditures, a less risky investment class than R&D, rose by $0.495 million per average firm after the rule took effect.

How solid is the causal claim?

The authors confront the obvious objection: maybe innovative firms simply disclose more risk, not the reverse. To address reverse causality and unobserved variables, they use an SEC rule from 2008 that exempted smaller reporting companies — those with revenues under $50 million — from risk disclosure, while firms above the threshold still had to comply.

A regression discontinuity design compares firms just above the threshold ($50 million to $100 million in revenue) with those just below it. These groups should be similar except that one is arbitrarily required to disclose and the other is not. The results: exempted smaller companies increased R&D by 1.644%, patent filings by 0.137%, citations per patent by 0.185%, and market value per patent by 0.249% relative to slightly larger firms still subject to the rule.

What drives the innovation drop?

The mechanism, according to the authors, is financing — not a change in engineering ambition. Firms that lacked internal cash produced much less innovation after the mandate. During recessions, when external capital dries up, the post-mandate innovation decline was steeper. Firms also became more likely to raise funds through equity issuances, a more expensive form of capital than debt.

The authors conclude the mandate either raised barriers to raising capital or increased the cost of capital for innovative firms, which in turn constrained R&D spending and output. For R&D portfolio planners, the implication is direct: disclosure obligations affect the price and availability of the capital that funds the pipeline.

The asymmetry at the heart of the problem is familiar to anyone managing early-stage technology. The authors point to the current AI race as an example: the risks are largely known — if the system fails, the invested money is wasted — while the benefits, such as potential productivity gains for office workers, resist quantification. Disclosure rules force firms to itemize the first category without a credible way to price the second.

The effect compounds at the portfolio level. Mandated risk disclosure makes less risky projects, such as exploratory-stage patents or capital expenditures, relatively more attractive to investors. The authors pose the question starkly: why invest in firm A's early-stage cancer cure when firm B's weight-loss drug has a proven market worth billions?

What should executives and regulators take from it?

For executives, the researchers argue the evidence reinforces that "disclosing less is more" when it comes to innovation. They note prior research showing that market scrutiny — going public, heavier analyst coverage — can already depress innovation. On this reading, mandatory risk disclosure compounds an existing drag by spooking investors away from firms pursuing uncertain technology.

For regulators, the authors argue the results show mandated disclosure can carry unintended consequences, and that the costs may be more substantial than previously anticipated. They recommend that rulemakers weigh both direct costs — filing expenses, legal fees, company time — and indirect costs, such as competitors gaining access to crucial information and the dampening effect on firm investment, when designing new disclosure requirements.

The study covers U.S. firms through 2010 and measures outcomes around a single regulatory event, so the magnitudes may not transfer directly to other jurisdictions or to disclosure regimes enacted since. But with AI investment now forcing exactly the risk-benefit asymmetry the authors describe, their framework is likely to be tested against whatever disclosure rules regulators write next.